Product: CXCR4 Antibody
Catalog: AF5279
Description: Rabbit polyclonal antibody to CXCR4
Application: WB IHC IF/ICC
Cited expt.: WB, IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Rabbit, Dog, Chicken
Mol.Wt.: 39 kDa; 40kD(Calculated).
Uniprot: P61073
RRID: AB_2837765

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(100%), Rabbit(100%), Dog(100%), Chicken(90%)
Clonality:
Polyclonal
Specificity:
CXCR4 Antibody detects endogenous levels of total CXCR4.
RRID:
AB_2837765
Cite Format: Affinity Biosciences Cat# AF5279, RRID:AB_2837765.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

C-X-C chemokine receptor type 4; CD184; CD184 antigen; Chemokine (C X C motif) receptor 4; Chemokine CXC Motif Receptor 4; CXC-R4; CXCR-4; CXCR4; CXCR4_HUMAN; D2S201E; FB22; Fusin; HM89; HSY3RR; LAP 3; LAP3; LCR1; LESTR; Leukocyte derived seven transmembrane domain receptor; Leukocyte-derived seven transmembrane domain receptor; Lipopolysaccharide associated protein 3; Neuropeptide Y receptor Y3; NPY3R; NPYR; NPYRL; NPYY3; NPYY3R; Probable G protein coupled receptor lcr1 homolog; SDF 1 receptor; SDF-1 receptor; SEVEN-TRANSMEMBRANE-SEGMENT RECEPTOR; Stromal cell derived factor 1 receptor; Stromal cell-derived factor 1 receptor; WHIM; WHIMS;

Immunogens

Immunogen:

A synthesized peptide derived from human CXCR4, corresponding to a region within C-terminal amino acids.

Uniprot:
Gene(ID):
Expression:
P61073 CXCR4_HUMAN:

Expressed in numerous tissues, such as peripheral blood leukocytes, spleen, thymus, spinal cord, heart, placenta, lung, liver, skeletal muscle, kidney, pancreas, cerebellum, cerebral cortex and medulla (in microglia as well as in astrocytes), brain microvascular, coronary artery and umbilical cord endothelial cells. Isoform 1 is predominant in all tissues tested.

Description:
Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ions levels and enhancing MAPK1/MAPK3 activation. Acts as a receptor for extracellular ubiquitin; leading to enhance intracellular calcium ions and reduce cellular cAMP levels
Sequence:
MEGISIYTSDNYTEEMGSGDYDSMKEPCFREENANFNKIFLPTIYSIIFLTGIVGNGLVILVMGYQKKLRSMTDKYRLHLSVADLLFVITLPFWAVDAVANWYFGNFLCKAVHVIYTVNLYSSVLILAFISLDRYLAIVHATNSQRPRKLLAEKVVYVGVWIPALLLTIPDFIFANVSEADDRYICDRFYPNDLWVVVFQFQHIMVGLILPGIVILSCYCIIISKLSHSKGHQKRKALKTTVILILAFFACWLPYYIGISIDSFILLEIIKQGCEFENTVHKWISITEALAFFHCCLNPILYAFLGAKFKTSAQHALTSVSRGSSLKILSKGKRGGHSSVSTESESSSFHSS

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Dog
100
Rabbit
100
Chicken
90
Sheep
0
Xenopus
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation. Involved in the AKT signaling cascade. Plays a role in regulation of cell migration, e.g. during wound healing. Acts as a receptor for extracellular ubiquitin; leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. Binds bacterial lipopolysaccharide (LPS) et mediates LPS-induced inflammatory response, including TNF secretion by monocytes. Involved in hematopoiesis and in cardiac ventricular septum formation. Also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells. Involved in cerebellar development. In the CNS, could mediate hippocampal-neuron survival (By similarity).

(Microbial infection) Acts as a coreceptor (CD4 being the primary receptor) for human immunodeficiency virus-1/HIV-1 X4 isolates and as a primary receptor for some HIV-2 isolates. Promotes Env-mediated fusion of the virus.

PTMs:

Phosphorylated on agonist stimulation. Rapidly phosphorylated on serine and threonine residues in the C-terminal. Phosphorylation at Ser-324 and Ser-325 leads to recruitment of ITCH, ubiquitination and protein degradation.

Ubiquitinated after ligand binding, leading to its degradation. Ubiquitinated by ITCH at the cell membrane on agonist stimulation. The ubiquitin-dependent mechanism, endosomal sorting complex required for transport (ESCRT), then targets CXCR4 for lysosomal degradation. This process is dependent also on prior Ser-/Thr-phosphorylation in the C-terminal of CXCR4. Also binding of ARRB1 to STAM negatively regulates CXCR4 sorting to lysosomes though modulating ubiquitination of SFR5S.

Sulfation on Tyr-21 is required for efficient binding of CXCL12/SDF-1alpha and promotes its dimerization. Tyr-7 and Tyr-12 are sulfated in a sequential manner after Tyr-21 is almost fully sulfated, with the binding affinity for CXCL12/SDF-1alpha increasing with the number of sulfotyrosines present. Sulfotyrosines Tyr-7 and Tyr-12 occupy clefts on opposing CXCL12 subunits, thus bridging the CXCL12 dimer interface and promoting CXCL12 dimerization.

O- and N-glycosylated. Asn-11 is the principal site of N-glycosylation. There appears to be very little or no glycosylation on Asn-176. N-glycosylation masks coreceptor function in both X4 and R5 laboratory-adapted and primary HIV-1 strains through inhibiting interaction with their Env glycoproteins. The O-glycosylation chondroitin sulfate attachment does not affect interaction with CXCL12/SDF-1alpha nor its coreceptor activity.

Subcellular Location:

Cell membrane>Multi-pass membrane protein. Cell junction. Early endosome. Late endosome. Lysosome.
Note: In unstimulated cells, diffuse pattern on plasma membrane. On agonist stimulation, colocalizes with ITCH at the plasma membrane where it becomes ubiquitinated. In the presence of antigen, distributes to the immunological synapse forming at the T-cell-APC contact area, where it localizes at the peripheral and distal supramolecular activation cluster (SMAC).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in numerous tissues, such as peripheral blood leukocytes, spleen, thymus, spinal cord, heart, placenta, lung, liver, skeletal muscle, kidney, pancreas, cerebellum, cerebral cortex and medulla (in microglia as well as in astrocytes), brain microvascular, coronary artery and umbilical cord endothelial cells. Isoform 1 is predominant in all tissues tested.

Family&Domains:

The amino-terminus is critical for ligand binding. Residues in all four extracellular regions contribute to HIV-1 coreceptor activity.

Belongs to the G-protein coupled receptor 1 family.

Research Fields

· Cellular Processes > Transport and catabolism > Endocytosis.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Organismal Systems > Immune system > Chemokine signaling pathway.   (View pathway)

· Organismal Systems > Development > Axon guidance.   (View pathway)

· Organismal Systems > Immune system > Leukocyte transendothelial migration.   (View pathway)

· Organismal Systems > Immune system > Intestinal immune network for IgA production.   (View pathway)

References

1). Enhanced Antiglioma Effect by a Vitamin D3-Inserted Lipid Hybrid Neutrophil Membrane Biomimetic Multimodal Nanoplatform. ACS nano, 2024 (PubMed: 39696957) [IF=17.1]

2). Reduction of Oxidative Stress and Excitotoxicity by Mesenchymal Stem Cell Biomimetic Co-Delivery System for Cerebral Ischemia-Reperfusion Injury Treatment. Small (Weinheim an der Bergstrasse, Germany), 2024 (PubMed: 38948959) [IF=13.0]

3). Ultrasound-targeted microbubble destruction promotes PDGF-primed bone mesenchymal stem cell transplantation for myocardial protection in acute Myocardial Infarction in rats. Journal of nanobiotechnology, 2023 (PubMed: 38102643) [IF=10.2]

4). Physiology‐Inspired Multilayer Nanofibrous Membranes Modulating Endogenous Stem Cell Recruitment and Osteo‐Differentiation for Staged Bone Regeneration. Advanced Healthcare Materials, 2022 (PubMed: 36027596) [IF=10.0]

5). Endothelial cell-derived MMP19 promotes pulmonary fibrosis by inducing E(nd)MT and monocyte infiltration. Cell communication and signaling : CCS, 2023 (PubMed: 36915092) [IF=8.4]

6). Single-cell RNA sequencing reveals small extracellular vesicles derived from malignant cells that contribute to angiogenesis in human breast cancers. Journal of translational medicine, 2023 (PubMed: 37626402) [IF=7.4]

Application: IF/ICC    Species: human    Sample: breast cancers

Fig. 5 Characterizing endothelial cell subsets within the tumor microenvironment of breast cancer. A Single-cell map showing endothelial cell subsets. B UMAP plots of 1425 endothelial cells from eight patient samples. C UMAP showing single-cell profiles of endothelial cells in the angiogenic and non-angiogenic groups. D Endothelial cell subcluster composition for different patients. E Scatter plot showing differences in the distribution of endothelial cell subclusters between angiogenic negative and positive groups. The ecology of angiogenic and non-angiogenic breast cancer groups. F–G Violin plot and UMAP figure showing the expression of markers related to angiogenesis and exosomes in these endothelial cell subsets and individual distribution. H Immunofluorescence images of CXCR4, S100A9 and PPP1R1B expression, which are highly specific in the angiogenesis group and distribution of marker genes. Scale bar, 20 µm. I Representative IHC images of gene signatures

7). TGF-β1-induced bone marrow mesenchymal stem cells (BMSCs) migration via histone demethylase KDM6B mediated inhibition of methylation marker H3K27me3. Cell Death Discovery, 2022 (PubMed: 35902563) [IF=7.0]

Application: WB    Species: Human    Sample: BMSCs

Fig. 1: The siRNA-KDM6B inhibited the migration of BMSCs in vitro. A The knockdown efficiency of KDM6B was verified by qRT-PCR. B, C The siRNA-KDM6B inhibited the protein expression of migration-related genes (N cadherin and CXCR4). D, E The IF showed the expression of CXCR4 was inhibited by siRNA-KDM6B. F, G The siRNA-KDM6B inhibited the actin cortical protrusions formation of BMSCs. H, I The scratch test showed that siRNA-KDM6B decreased the migration area of BMSCs. J, K Transwell test verified that siRNA-KDM6B inhibited the migrated MSCs number. (si-1: siKDM6B-1, si-2: siKDM6B-2, si-3: siKDM6B-3. *P 

8). Umbilical cord mesenchymal stem cells overexpressing CXCR7 facilitate treatment of ARDS-associated pulmonary fibrosis via inhibition of Notch/Jag1 mediated by the Wnt/β-catenin pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023 (PubMed: 37454589) [IF=6.9]

Application: WB    Species: Mouse    Sample: UCMSCs

Fig. 3. Long-term expression efficiency of CXCR4 and CXCR7 in UCMSCs after lentiviral vector transduction. (a) The UCMSCs transduced separately with pHBLV-CMVIE-ZsGreen-T2A-puromycin (UCMSCsOE-NC), pHBLV-CMVIE-CXCR4-ZsGreen-T2A-puromycin (UCMSCsOE-CXCR4) and pHBLV-CMVIE-CXCR7-ZsGreen-T2A-puromycin (UCMSCsOE-CXCR7) lentiviral vectors were cultured for 20 passages and observed by light microscopy (top) and fluorescence microscopy with a green fluorescent protein (bottom), 100×. (b) At passage 20 after transduction, the immunophenotype of UCMSCsOE-CXCR7 was analyzed by flow cytometry. Adherent UCMSCs were positive for CD29, CD73, CD105 and CD166 but negative for CD11b, CD34, CD45 and HLA-DR. Isotype-matched controls were used for comparison. Immunophenotype analysis of UCMSCs and UCMSCsOE-CXCR4 by flow cytometry is described in Supplementary Figure 1b-c (Fig. 1S b-c). (c) Determination of CXCR7 mRNA expression in UCMSCs by qRT-PCR analysis after pHBLV-CMVIE-ZsGreen-T2A-puromycin, pHBLV-CMVIE-CXCR4-ZsGreen-T2A-puromycin and pHBLV-CMVIE-CXCR7-ZsGreen-T2A-puromycin transduction. (d) Western blot analysis showed increased CXCR7 and CXCR4 protein expression in transduced UCMSCs. * ** *p 

9). B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer. iScience, 2024 (PubMed: 39319269) [IF=5.8]

10). Silencing c-Myc Enhances the Antitumor Activity of Bufalin by Suppressing the HIF-1α/SDF-1/CXCR4 Pathway in Pancreatic Cancer Cells. Frontiers in Pharmacology, 2020 (PubMed: 32362830) [IF=5.6]

Application: WB    Species: Human    Sample: pancreatic cancer cells

Figure 6 Downregulation of c-Myc enhanced the antitumor effect of bufalin in pancreatic cancer cells through the HIF-1α/SDF-1/CXCR4 pathway. (A) The protein expression of c-Myc, vimentin, E-cadherin, HIF-1α, CXCR4, and SDF-1 in PANC-1 and SW1990 pancreatic cancer cells under different treatments was detected via western blot. (B) Quantification results of protein expressions of c-Myc, vimentin, E-cadherin, HIF-1α, CXCR4, and SDF-1 in PANC-1 pancreatic cancer cells. (C) Quantification results of protein expression of c-Myc, vimentin, E-cadherin, HIF-1α, CXCR4, and SDF-1 in SW1990 pancreatic cancer cells (* p < 0.05, ** p < 0.01 vs control, ▲ p < 0.05, ▲▲ p < 0.01 vs bufalin treatment group, n = 3).

Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.